IL294666B2 - A salt of a derivative compound of aminopyridine, its crystalline form and a process for its preparation - Google Patents
A salt of a derivative compound of aminopyridine, its crystalline form and a process for its preparationInfo
- Publication number
- IL294666B2 IL294666B2 IL294666A IL29466622A IL294666B2 IL 294666 B2 IL294666 B2 IL 294666B2 IL 294666 A IL294666 A IL 294666A IL 29466622 A IL29466622 A IL 29466622A IL 294666 B2 IL294666 B2 IL 294666B2
- Authority
- IL
- Israel
- Prior art keywords
- mesylate salt
- crystalline form
- compound
- graph
- use according
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
- C07C303/02—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of sulfonic acids or halides thereof
- C07C303/22—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of sulfonic acids or halides thereof from sulfonic acids, by reactions not involving the formation of sulfo or halosulfonyl groups; from sulfonic halides by reactions not involving the formation of halosulfonyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20170051687 | 2017-04-21 | ||
| PCT/KR2018/004473 WO2018194356A1 (en) | 2017-04-21 | 2018-04-18 | Salt of an aminopyridine derivative compound, a crystalline form thereof, and a process for preparing the same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL294666A IL294666A (en) | 2022-09-01 |
| IL294666B1 IL294666B1 (en) | 2024-01-01 |
| IL294666B2 true IL294666B2 (en) | 2024-05-01 |
Family
ID=63857137
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL294666A IL294666B2 (en) | 2017-04-21 | 2018-04-18 | A salt of a derivative compound of aminopyridine, its crystalline form and a process for its preparation |
| IL270018A IL270018B (en) | 2017-04-21 | 2018-04-18 | A salt of a derivative compound of aminopyridine, its crystalline form and a process for its preparation |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL270018A IL270018B (en) | 2017-04-21 | 2018-04-18 | A salt of a derivative compound of aminopyridine, its crystalline form and a process for its preparation |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US11453656B2 (enExample) |
| EP (1) | EP3612529A4 (enExample) |
| JP (2) | JP7126514B2 (enExample) |
| KR (3) | KR102629654B1 (enExample) |
| CN (1) | CN110869367B (enExample) |
| AR (1) | AR111469A1 (enExample) |
| AU (2) | AU2018256227B2 (enExample) |
| BR (1) | BR112019021868A2 (enExample) |
| CA (1) | CA3059543A1 (enExample) |
| CO (1) | CO2019011578A2 (enExample) |
| EA (1) | EA201992501A1 (enExample) |
| IL (2) | IL294666B2 (enExample) |
| MA (1) | MA49696A (enExample) |
| MX (2) | MX392634B (enExample) |
| MY (1) | MY201919A (enExample) |
| NZ (1) | NZ758443A (enExample) |
| PH (1) | PH12019502370A1 (enExample) |
| SA (1) | SA519410342B1 (enExample) |
| SG (1) | SG11201909615YA (enExample) |
| TW (1) | TWI776882B (enExample) |
| UA (1) | UA124364C2 (enExample) |
| WO (1) | WO2018194356A1 (enExample) |
| ZA (1) | ZA201907687B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR111469A1 (es) * | 2017-04-21 | 2019-07-17 | Yuhan Corp | Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma |
| MD3658552T2 (ro) | 2017-07-28 | 2024-02-29 | Yuhan Corp | Procedeu de obținere a N-(5-((4-(4-((dimetilamino)metil)-3-fenil-1H-pirazol-1-il)pirimidin-2-il)amino)-4-metoxi-2-morfolinofenil)acrilamidei prin prin reacţia aminei corespunzătoare cu clorură de 3-halo-propionil |
| KR20200043618A (ko) * | 2018-10-18 | 2020-04-28 | 주식회사유한양행 | 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물 |
| KR101973074B1 (ko) * | 2018-11-30 | 2019-04-26 | 주식회사 티움바이오 | 퓨로피리미딘 화합물의 염 및 결정형, 및 이를 포함하는 약학적 조성물 |
| EP3885346A4 (en) * | 2018-12-21 | 2022-01-12 | Shenzhen TargetRx, Inc. | Aminopyrimidine compound used for inhibiting activity of protein kinase |
| EP3931224A4 (en) | 2019-02-26 | 2023-03-01 | Janssen Biotech, Inc. | COMBINATION TREATMENTS AND PATIENT STRATIFICATION WITH ANTI-EGFR/C-MET BISPECIFIC ANTIBODIES |
| MX2021013955A (es) * | 2019-05-14 | 2022-03-11 | Janssen Biotech Inc | Terapias de combinación con anticuerpos anti-egfr/c-met biespecíficos e inhibidores de tirosina quinasa de egfr de 3.a generación. |
| WO2020230091A1 (en) * | 2019-05-14 | 2020-11-19 | Janssen Biotech, Inc. | Combination therapies with bispecific anti-egfr/c-met antibodies and third generation egfr tyrosine kinase inhibitors |
| US11850248B2 (en) * | 2019-05-14 | 2023-12-26 | Yuhan Corporation | Therapies with 3rd generation EGFR tyrosine kinase inhibitors |
| JOP20220184A1 (ar) | 2020-02-12 | 2023-01-30 | Janssen Biotech Inc | علاج مصابي السرطان ممن لديهم طفرات تخطي c-Met إكسون14 |
| TW202207940A (zh) * | 2020-04-14 | 2022-03-01 | 美商健生生物科技公司 | 包含胺基嘧啶衍生物或其醫藥上可接受之鹽、水合物、或溶劑化物之用於經口投予之醫藥組成物 |
| WO2022253261A1 (zh) | 2021-06-01 | 2022-12-08 | 杭州领业医药科技有限公司 | Lazertinib甲磺酸盐的水合物晶型及其制备方法和用途 |
| CA3228195A1 (en) | 2023-05-23 | 2025-06-30 | Janssen Biotech Inc | Methods for treatment of non-small cell lung cancer (nsclc) |
| WO2025052273A1 (en) | 2023-09-05 | 2025-03-13 | Janssen Biotech, Inc. | Methods of treating non-small cell lung cancer |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160102076A1 (en) * | 2014-10-13 | 2016-04-14 | Yuhan Corporation | Compounds and compositions for modulating egfr mutant kinase activities |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005063713A1 (ja) | 2003-12-25 | 2005-07-14 | Eisai Co., Ltd. | ４−（３−クロロ−４−（シクロプロピルアミノカルボニル）アミノフェノキシ）−７−メトキシ−６−キノリンカルボキサミドの塩またはその溶媒和物の結晶およびそれらの製造方法 |
| CA2555804C (en) | 2004-02-11 | 2012-06-26 | Natco Pharma Limited | Polymorphic form of imatinib mesylate and a process for its preparation |
| NZ624345A (en) * | 2008-06-27 | 2016-07-29 | Celgene Avilomics Res Inc | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| CZ2009570A3 (cs) | 2009-08-26 | 2011-03-09 | Zentiva, K. S. | Príprava, stabilizace a využití polymorfu imatinib mesylátu pro vývoj lékových forem |
| EP2498607B1 (en) * | 2009-11-13 | 2016-02-17 | Genosco | Kinase inhibitors |
| EP2649060B1 (en) * | 2010-12-06 | 2017-04-05 | MSN Laboratories Limited | Process for the preparation of benzimidazole derivatives and its salts |
| EP3333161B1 (en) | 2011-07-27 | 2020-02-19 | Astrazeneca AB | 2-(2,4,5-substituted-anilino)pyrimidine derivatives as egfr modulators useful for treating cancer |
| CN104540822B (zh) | 2013-07-08 | 2016-08-31 | 杭州普晒医药科技有限公司 | 达拉菲尼甲磺酸盐的晶型及其制备方法 |
| CN106687457B (zh) | 2014-05-13 | 2020-01-10 | 阿里亚德医药股份有限公司 | 用于激酶抑制的杂芳基化合物 |
| CN104788427B (zh) * | 2015-02-05 | 2017-05-31 | 上海泓博智源医药股份有限公司 | 3‑(2‑嘧啶氨基)苯基丙烯酰胺类化合物及其应用 |
| KR101794186B1 (ko) | 2015-10-30 | 2017-11-08 | 한국기술교육대학교 산학협력단 | 전기자동차용 급전장치 |
| AR111469A1 (es) | 2017-04-21 | 2019-07-17 | Yuhan Corp | Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma |
| KR20200043618A (ko) | 2018-10-18 | 2020-04-28 | 주식회사유한양행 | 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물 |
-
2018
- 2018-04-13 AR ARP180100945A patent/AR111469A1/es unknown
- 2018-04-18 IL IL294666A patent/IL294666B2/en unknown
- 2018-04-18 EP EP18787260.1A patent/EP3612529A4/en active Pending
- 2018-04-18 EA EA201992501A patent/EA201992501A1/ru unknown
- 2018-04-18 TW TW107113234A patent/TWI776882B/zh active
- 2018-04-18 WO PCT/KR2018/004473 patent/WO2018194356A1/en not_active Ceased
- 2018-04-18 MY MYPI2019006145A patent/MY201919A/en unknown
- 2018-04-18 CN CN201880026342.7A patent/CN110869367B/zh active Active
- 2018-04-18 US US16/605,944 patent/US11453656B2/en active Active
- 2018-04-18 CA CA3059543A patent/CA3059543A1/en active Pending
- 2018-04-18 JP JP2019556610A patent/JP7126514B2/ja active Active
- 2018-04-18 KR KR1020180044850A patent/KR102629654B1/ko active Active
- 2018-04-18 UA UAA201911263A patent/UA124364C2/uk unknown
- 2018-04-18 MA MA049696A patent/MA49696A/fr unknown
- 2018-04-18 IL IL270018A patent/IL270018B/en unknown
- 2018-04-18 SG SG11201909615Y patent/SG11201909615YA/en unknown
- 2018-04-18 MX MX2019012574A patent/MX392634B/es unknown
- 2018-04-18 AU AU2018256227A patent/AU2018256227B2/en active Active
- 2018-04-18 BR BR112019021868-8A patent/BR112019021868A2/pt active Search and Examination
- 2018-04-18 NZ NZ758443A patent/NZ758443A/en unknown
-
2019
- 2019-10-18 CO CONC2019/0011578A patent/CO2019011578A2/es unknown
- 2019-10-18 PH PH12019502370A patent/PH12019502370A1/en unknown
- 2019-10-20 SA SA519410342A patent/SA519410342B1/ar unknown
- 2019-10-21 MX MX2022006357A patent/MX2022006357A/es unknown
- 2019-11-20 ZA ZA2019/07687A patent/ZA201907687B/en unknown
-
2022
- 2022-03-17 US US17/697,655 patent/US11981659B2/en active Active
- 2022-05-23 AU AU2022203486A patent/AU2022203486B2/en active Active
- 2022-08-16 JP JP2022129468A patent/JP7390444B2/ja active Active
-
2023
- 2023-12-18 KR KR1020230184208A patent/KR102835717B1/ko active Active
-
2024
- 2024-03-27 US US18/618,379 patent/US12428401B2/en active Active
-
2025
- 2025-07-11 KR KR1020250093917A patent/KR20250111074A/ko active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160102076A1 (en) * | 2014-10-13 | 2016-04-14 | Yuhan Corporation | Compounds and compositions for modulating egfr mutant kinase activities |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11981659B2 (en) | Salt of an aminopyridine derivative compound, a crystalline form thereof, and a process for preparing the same | |
| JPWO2002062775A1 (ja) | ２−アシルアミノチアゾール誘導体又はその塩 | |
| JP6970691B2 (ja) | Ｔｒｐｖ４拮抗薬 | |
| CN113015521A (zh) | 用于口服的包含氨基嘧啶衍生物或其盐的药物组合物 | |
| US20230303541A1 (en) | Heterocyclic compounds useful as modulators of acetylcholine receptors | |
| KR101929725B1 (ko) | 의학적 적용을 위한 3-(1,2,4-트리아졸로[4,3-a]피리딘-3-일에티닐)-4-메틸-N-(4-((4-메틸피페라진-1-일)메틸)-3-트리플루오로메틸페닐)벤즈아미드의 신규 결정질 염 형태 | |
| TW202128666A (zh) | 氨基嘧啶類化合物甲磺酸鹽的晶型a及其製備方法和應用 | |
| WO2023064223A1 (en) | Tri-substituted pyridines | |
| EA041089B1 (ru) | Соль соединения производного аминопиридина, ее кристаллическая форма и способ получения | |
| HK40025158B (zh) | 氨基吡啶衍生物化合物的盐、其结晶形式、以及用於制备它们的方法 | |
| HK40025158A (en) | Salt of an aminopyridine derivative compound, a crystalline form thereof, and a process for preparing the same | |
| WO2010083649A1 (zh) | 双芳基脲类衍生物及用途 | |
| JP2003342175A (ja) | 新規なベンゾアゼピン誘導体又はその塩を有効成分とするメニエール病治療剤 | |
| JP2024540004A (ja) | キナゾリン誘導体化合物およびその用途 | |
| BRPI0616682A2 (pt) | derivados de quinazolina e produtos farmacêuticos | |
| EA046959B1 (ru) | Фармацевтическая композиция для перорального введения, содержащая производное аминопиримидина или его соль | |
| EA040294B1 (ru) | Фторопиперидиновые соединения в качестве чистых антагонистов 5-ht6-рецептора |